Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Mol Cancer Res. 2021 Oct 11;20(1):45–55. doi: 10.1158/1541-7786.MCR-21-0442

Figure 1.

Figure 1.

Clinical and genomic features of patient MSK-THY1 with differentiated thyroid cancer that underwent anaplastic transformation subsequent to treatment with vemurafenib. A, Clinical timeline with major events indicated. Serial radiographic images illustrate progression of papillary thyroid cancer to widely disseminated anaplastic malignancy. Time of imaging relative to vemurafenib start date is provided for each image and areas of disease are indicated by arrows. Panel 1: PET/CT, Panels 2-4: CT with contrast, Panel 5: T1-weighted MRI with contrast, RAI: radioactive iodine, PR: partial response, ATC: anaplastic thyroid cancer. B & C, Pre-treatment and post-transformation hematoxylin-and-eosin-stained slides show histologic transformation from papillary to anaplastic thyroid carcinoma. D, Number of shared and exclusive mutations in classic-type papillary thyroid cancer (PTC) compared to anaplastic metastases (ATC Met 1 & ATC Met 2). E, Landscape of single nucleotide variants of the PTC tumor and ATC metastases. Each mutation color coded by cancer cell fraction (CCF). Unsupervised hierarchical clustering identified subsets of related samples and mutations.